BTC Capital Management Inc. Purchases 1,172 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

BTC Capital Management Inc. boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 12.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,623 shares of the specialty pharmaceutical company’s stock after buying an additional 1,172 shares during the quarter. BTC Capital Management Inc. owned approximately 0.05% of ANI Pharmaceuticals worth $587,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in ANIP. State Street Corp raised its position in shares of ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after acquiring an additional 58,698 shares during the last quarter. Pacer Advisors Inc. raised its holdings in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after purchasing an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. increased its position in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after buying an additional 9,500 shares during the period. Finally, Geode Capital Management LLC raised its stake in ANI Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after buying an additional 17,314 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $58.64 on Friday. The company has a market cap of $1.23 billion, a P/E ratio of -106.62 and a beta of 0.73. The company has a fifty day simple moving average of $56.61 and a 200 day simple moving average of $58.60. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same period last year, the company earned $1.05 earnings per share. The business’s revenue was up 12.5% on a year-over-year basis. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,381 shares of company stock worth $2,441,556 over the last 90 days. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.